Thanks for coming. See you next year.
Back to top
Conference News

Attend a satellite session

10 Oct 2018

Satellite sessions are organised and supported by individuals, non-profit groups, organisations, or commercial entities. The Union offers these groups the opportunity to showcase their work, research and programmes, or draw more attention to a specific subject or area by organising a satellite.

Satellite sessions will be held from 25-27 October outside of the core programme hours. Morning sessions will run for 75 minutes and evening sessions will be allotted 90 minutes.

Here are full details of the Satellite Sessions:

Thursday 25 October

07.30 – 08.45

Advancing host-directed therapies for tuberculosis

Organised by: National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID)

This satellite session will cover recent developments in the field of host-directed therapies (HDT) for TB, including a discussion of immune regulatory pathways and immune cell types that have been targeted successfully to enhance host clearance of mycobacteria and/or reduce lung inflammation in pre-clinical models. A roadmap will be provided for clinical evaluation of novel HDT agents against TB, with an emphasis on the repurposing of drugs developed for other diseases, given the reduced costs associated with their clinical application in resource-limited settings. Read more…

07.30 – 08.45

Breaking the silos: multi-sectoral action for tuberculosis elimination

Organised by: Challenge TB

 TB has a devastating impact not only on the health and wellbeing of people around the world, but also on the economic growth and stability of the countries. According to a recent research commissioned by the Global TB Caucus, if global efforts to tackle TB continue at the same rate of progress, from 2015–2050, 28 million people will lose their lives to TB, at a global economic cost of $983 billion. Recognizing the need to accelerate the response, the World Health Organization is calling for a radical new approach to tackle TB. The social and economic drivers of the epidemic mean that TB cannot be beaten by the health sector alone; instead “a dynamic, global, multisectoral approach” is needed. For accelerated efforts for TB elimination, it is more important than ever to develop creative alliances between governments, academic, civil society and private sectors. Read more…

07.30 – 08.45

Scalable MTB and resistance testing on a polyvalent platform for centralized laboratories serving both low Incidence and high burden settings

Organised by: Roche

This session will provide an overview of two studies that evaluated cobas® MTB and cobas® RIF/INH for use on the cobas® 6800/8800 Systems from sputum and sediment specimens. The first study examined assay performance in a high burden HIV population. The second study evaluated assay sensitivity and specificity at the National Reference Center in Germany serving both low incidence and high burden settings. Read more…

18.00 – 19.30

As part of the global healthcare community, how can we impact the TB patient pathway and overcome existing challenges?

Organised by: BD

This session will offer two areas of focus. The first will be the preliminary multi-center clinical trial results of the BD MAX™ MDR-TB molecular test, which detects Mycobacterium tuberculosis complex and resistance to both RIF and INH all in one test. We will then convene a panel of global TB experts. Moderated by Renuka Gadde, Vice President of BD Global Health, panelists will include experts from global organizations such as WHO, USAID, FIND, McGill Global Health & Johns Hopkins Med Ctr programmes. This will be an interactive symposium with a question-and-answer session. This discussion will focus on how the healthcare community can best support the elimination of TB, by leveraging current and future technologies, despite existing challenges. Read more…

18.00 – 19.30

Back to the future: “High performance automated chest radiography as primary triage for Tuberculosis and respiratory symptomatics”

Organised by: Qure-ai 

Furthering the agenda of previous CXR symposiums in Cape Town (2015) & Liverpool (2016) – the symposia will focus on highlighting the present and future of CXR radiology. A panel of expert stakeholders will present their ongoing experience in deploying X-ray hardware and CAD software and discuss the mandate for the future of CXR as a primary screening test for lung symptomatics in the context of UHC and TB 2025 agenda. Read more…

18.00 – 19.30

Breaking down the barriers to quality TB/HIV care—tools and approaches addressing self-stigma and stigma in healthcare institutions in Kazakhstan

Organised by: KNCV Tuberculosis Foundation

In this session we are introducing the concept of TB stigma, and the two toolkits, and share our experiences of implementing both tools in Kazakhstan and provide an opportunity of experiencing the tools and a selection of sessions first-hand.
The tools were developed to be easily accessible, adaptable and flexible to fit a multitude of environments and audiences. The training session is divided into short (30 min) interactive modules. Read more…

18.00 – 19.30

Identifying and addressing ototoxicity due to secondline injectable drugs in the treatment of drug-resistant tuberculosis

Organised by: Johnson & Johnson

This session will seek to inform healthcare providers, TB programme managers and others involved in the planning and the delivery of care to MDR-TB patients:

  1. the extent of ototoxicity associated with MDR-TB treatment and the toxic effects of SLI drugs;
  2. how to incorporate robust and cost-effective ways of monitoring for hearing loss during the treatment of MDR TB under programmatic settings: and
  3. how the use of new or repurposed drugs might help mitigate hearing loss associated with the use of the injectable drugs.

Read more…

18.00 – 19.30

Improving the quality of TB services and data: a path forward

Organised by: John Snow Inc

The tuberculosis community is focused on achieving the End TB Strategy goals of reducing incidence by 80% within the next twelve years. Achievement of the End TB goals will depend on the quality of care provided by individual countries, as most patients have access to health facilities and are covered by national TB programmes. This satellite session will illustrate where quality of care is often poor and the consequences this can have. The session’s objective is to indicate where improvements in policies and in implementation can be made at the national level. Read more…

18.00 – 19.30

Mobiles, dashboards, and the Internet of things: harnessing innovative digital technologies to improve data and treatment adherence in three global regions

Organised by: KNCV Tuberculosis Foundation

Using mobile phones, data networks and web systems, digital adherence technologies can play an important role to support patient centered approaches, improve adherence, persistence on treatment and eventually TB treatment success rates by facilitating data-driven, differentiated TB care.
This KNCV hosted satellite symposium will present an overview of digital adherence technologies; updates on recent evidence; experiences from two countries that are preparing implementation and from two countries that are in scale-up phase of technologies. Also a data analytics framework for technology engagement, differentiated care and impact measurement will be introduced. Read more…

18.00 – 19.30

Regional prospective observational research in TB (RePORT) India: biomarkers, diagnostics and comorbidities

Organised by: National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID)

RePORT India is a bilateral, multi-organizational, collaborative research effort established in 2013 under the Indo-US Vaccine Action Program. The consortium consists of seven clinical research site cohorts in India and five partnering US academic sites. The cohorts have well-characterized TB cases and contacts and systematic biobanking for epidemiology, immunology, and biomarker discovery research to address TB in India and beyond. RePORT India is one of six regional consortia worldwide. The objective of this symposium is to share key findings from RePORT India studies that can be applied to improve TB programmes and advance biomarker and vaccine research in high-burden settings. Read more…

18.00 – 19.30

Shorter MDR-TB Treatment Regimen why, for whom, and how: evidence to overcome implementation challenges

Organised by: Damien Foundation

In 2016, the World Health Organization (WHO) recommended the Shorter-Treatment-Regimen (STR). Implementation of the cheaper and simplified standardized STR potentially would achieve high-efficacy in many settings. In 2017, 35 countries were implementing the STR, but rationale, indications and the operationalization of STR were not fully understood and the guidelines for its implementation have been made unnecessarily complicated. During the presentations followed by a panel discussion, STR-experts will review current evidence including recently reported seemingly disappointing clinical trial results, and the possible reasons for this. Read more…

Friday 26 October

07.30 – 08.45

Breaking beta: heterogeneity in tuberculosis transmission and its impact on model projections

Organised by: Institute for Disease Modeling 

This session focuses on the evidence for heterogeneous TB transmission and its impact on projections of TB burden and control. We begin with an overview of recent methods to quantify transmission including shared air monitoring and respiratory aerosol sampling, citing examples from South Africa. Next we present several modeling viewpoints. Models typically represent transmission by a single averaged parameter denoted beta. However, stratifying beta may have distinct advantages. Read more…

07.30 – 08.45

Panel discussion—TB control in refugees, migrants and internally displaced populations: early lessons from the Middle East region

Organised by: IOM – The UN Migration Agency Jordan

Protracted conflicts in the Middle East have caused a region-wide health crisis. Millions are displaced internally and hundreds of thousands are leaving their country to become refugees. Approximately 6.3 million Syrians have taken asylum worldwide, mostly in neighbouring countries. The protracted war in Iraq has displaced three million, while years of war in Yemen have resulted in 22.2 million people in need of humanitarian assistance. Population displacement coupled with destruction of health infrastructure poses challenges to TB control. This symposium will share early lessons from supporting ministries of health and national TB programmes in Yemen, Syria, Iraq, Jordan and Lebanon. Read more…

07.30 – 08.45

TB and human rights: successes, challenges and opportunities

Organised by: United Nations Development Programme (UNDP) 

In July 2018, the Global Commission on HIV and the Law released a supplement to its landmark report of 2012- Risks, Rights, & Health. The 2018 supplement addresses barriers to a rights-based response to TB and makes several recommendations to governments aimed at creating an enabling legal and rights environment for an effective response to TB.

The satellite session will discuss the recommendations of the 2018 Supplement and examine various strategies and examples of how rights-based, evidence-informed approaches can bolster the global response to TB, including through legal environment assessments, and partnerships with the legislature, judiciary and civil society groups. Read more…

07.30 – 08.45

The first thousand bedaquiline courses—how is India providing access to new drugs and regimens

Organised by: Challenge TB

The Revised National TB Control Programme (RNTCP) in India made Bedaquiline accessible to Drug Resistant TB patients at six initial sites in 2016, under Conditional Access Programme (CAP). In 2017, the access was expanded across the country. In 2018, the country has rolled out the use of Delamanid and Shorter Treatment Regimen under Programmatic Management of Drug Resistant TB (PMDT). The symposium will highlight the country response in terms of the challenges, policy amendments, preparations, during the introduction and scaling of access to new drugs and regimens. Read more…

07.30 – 08.45

Uncovering the Missing Millions: Impact of New TB Diagnostic tools

Organised by: Cepheid 

In this symposium the panel will discuss the impact and limitations of Xpert MTB/RIF and new possibilities with Xpert MTB/RIF Ultra for TB and MDR testing, its applicability for paediatric testing and multiplexing. Xpert MTB/RIF Ultra offers a faster time to result on the GeneXpert® platform, thus freeing up capacity on existing devices for additional TB testing and giving room for polyvalent near-care diagnostics testing for HIV, HCV and HPV, a clear opportunity for programmes to integrate and work more closely together. Read more…

18.00 – 19.30

Ensuring the rights to rapid and quality diagnosis, treatment and care for TB in countries of Eastern Europe and Central Asia: challenges, achievements and perspectives

Organised by: WHO EURO Joint Tuberculosis, HIV/AIDS & Hepatitis (JTH) programme

Despite a steady decline in the number of new TB cases and TB deaths globally and in European region, the countries of Eastern Europe and Central Asia (EECA) have become the global center of MDR-TB crisis with the highest levels of MDR/XDR-TB ever recorded. Simultaneously, the incidence of TB/HIV co-infection and TB/HIV mortality have been increasing and added additional challenges to healthcare systems of EECA countries. In order to address these problems, EECA countries have introduced many successful initiatives and started moving towards more people-centred models of TB care. In line with the 2018 Union conference theme, this year’s EECA session will focus on possible effective solutions to the emerging challenges in order to ensure the rights to prevention, rapid and quality diagnosis, treatment and care for TB. Read more…

18.00 – 19.30

Harnessing the full potential of private providers across the TB cascade of care

Organised by: FHI 360 

More than 60% of the 4 million “missing people” with TB in 2016 were in six countries in which private providers accounted for more than two thirds of initial care for the population. However, in these countries, the contribution of private for-profit providers was equivalent to only 9% of estimated TB incidence. Many of the “missing people” are unreached by health services because of weak health systems, lack of universal health coverage and the presence of financial and socio-cultural barriers, particularly for vulnerable and marginalized populations. Many remain undiagnosed after reaching health services because of weak referral pathways between private sector and other health care providers, and the lack/poor enforcement of mandatory case notification. Countries are moving towards Universal Health Coverage (UHC) and reaching the TB-related targets in the Sustainable Development Goals and End TB Strategy. Ensuring early access to TB diagnosis and treatment and reducing unnecessary death and suffering requires countries to harness the full potential of private providers. This satellite session will discuss the evidence base and rationale for the effectiveness of private sector engagement towards TB elimination, with a focus on lessons learnt from high burden countries. Read more…

18.00 – 19.30

Lessons learnt from the West African regional network for tuberculosis control (WARN-TB) for improving TB control in West Africa

Organised by: International Union Against Tuberculosis and Lung Disease (The Union), Damien Foundation and WHO/TDR 

The African-region is the second region most affected by tuberculosis worldwide with 2.6 million people affected in 2016 out of 10.4 million worldwide. The African-response to this burden included rapid uptake of WHO guidelines and public-health based approaches to control TB. In June 2015, 16 countries of the region created the West African regional network for Tuberculosis Control (WARN-TB) aiming exchanges and harmonization of best-practices, implementation-research and advocating for resource-mobilisation. The initiative is supported by regional partners including The Union, Damien Foundation, WAHO, GFATM, WHO, and TDR. We share in this presentation progress achieved after three years of WARN-TB creation. Read more…

18.00 – 19.30

Preserving our future—protecting children from TB infection, disease and death

Organised by: KNCV Tuberculosis Foundation

This Symposium provides an overview of the global childhood TB epidemic, presents the new 2nd edition of the Childhood TB Roadmap, and the KNCV Childhood TB Benchmarking tool to help countries to assess the status of their own childhood TB interventions against the Childhood TB Roadmap and develop their own country specific policies, strategy and roadmap in response.
The symposium further explores new and improved child-friendly ways towards prevention, early detection, improved diagnosis, and management of latent childhood TB.
Read more…

18.00 – 19.30

Prevention of phenotypic resistance testing of Mycobacterium tuberculosis isolates by whole genome sequencing

Organised by: National Institute for Public Health and the Environment (RIVM) 

In this symposia speakers will highlight the possibilities to determine the susceptibility of Mycobacterium tuberculosis isolates to antituberculosis drugs no longer by phenotypic, time consuming tests, but by investigating the presence/absence of mutations associated with resistance. The negative predictive value of Whole Genome Sequencing for resistance is extremely high and this should lead to stopping with most of the drug susceptibility testing for cases in which absence of resistance mutations is confirmed. In addition, there will be presentations on the association of resistance mutations and treatment outcome to emphasize possibilities to steer the therapy on basis of molecular diagnosis. Read more…

18.00 – 19.30

Role of artificial intelligence and chest radiography for the detection of tuberculosis and other lung diseases

Organised by: Delft Imaging

Digital chest radiography is increasingly used to screen for tuberculosis. Used as a triage test to select individuals for bacteriological testing, it allows for screening large groups of TB suspects at low costs. Chest radiography is also essential for the diagnosis and monitoring of many other lung diseases. Artificial intelligence is a rapidly developing field and increasingly applied to medical image analysis. The first products for chest radiography analysis have appeared on the market. In this symposium we show and discuss progress and application of chest radiography and artificial intelligence to the detection of TB and other lung diseases. Read more…

Saturday 27 October

07.30 – 08.45

Cracking the aDSM conundrum in resource limited settings—safeguarding patients whilst introducing new drugs and regimens for DRTB in India

Organised by: Challenge TB and The Union South-East Asia Office

Pharmacovigilance and proper management of adverse drug reactions and prevention of drug–drug interactions, is one of the most important and challenging five conditions that must be met for the inclusion of bedaquiline in the adult treatment regimen of MDR-TB, in accordance with the WHO Interim Guide for Bedaquiline Use (2013). The speakers in this symposium will talk about how the Pharmacovigilance and active Drug Safety Monitoring and Management (aDSM) system was established at the initial six Bedaquiline Conditional Access Programme (CAP) sites in India; lessons from Cohort Event Monitoring; and how to address the challenges in managing Adverse Drug Reactions under programmatic settings. Read more…


Follow Us

RT @UnionConference: The #UnionConf #TBScience event in Hyderabad, India on 29 and 30 October is devoted to basic and translational #tuberc

The #UnionConf #TBScience event in Hyderabad, India on 29 and 30 October is devoted to basic and translational…

Receive Conference News & Updates